GLG Network Survey: Cheplapharm

Please fill out the form to request access to the survey data

SURVEY DETAILS
TARGET POPULATION

For this Network Survey, GLG surveyed 20 physicians based in Germany, who are knowledgeable about Cheplapharm.

What will you learn from this survey?

  • Respondents commented on current scenario of the German pharmaceutical industry including change in size of market, market leaders, level of innovation and frequency of prescription for each player.
  • The research also looked into current issues faced by Cheplapharm and assessed its business model, covering issues such as product availability and acquisition challenges, and deep diving into strengths and weaknesses of the company.
  • Lastly, the survey captured respondents’ views on the future outlook for the company, including expectations of further acquisitions, expected time to gain back lost market share, change in profitability and ideal steps that should be taken by the company.

Examples of findings:

  • Six-in-ten (60%) respondents believe that Cheplapharm is currently facing a moderate challenge regarding product availability. Furthermore, almost six-in-ten (58%) state that these challenges are creating minor issues in prescription and usage.
  • Six-in-ten (60%) claim that Cheplapharm will continue to undertake more acquisitions in the next 5 years, but at a lower pace.
  • One-fifth (20%) of respondents claim that Cheplapharm’s greatest strengths are global distribution and niche therapeutic areas, while one-fourth (25%) think its greatest weakness is its strategic acquisitions.

Deliverables

The GLG Surveys team drafted the questionnaire with the support of GLG Network Member, Jens Rothstein, former CFO at Cheplapharm.

  • 1 x Individual responses (“raw data”) in Excel.
  • 1 x PPT report with aggregated data.
  • Executive summary with key takeaways and highlights from the raw data.

Sample Questions

  • What is the level of product availability/supply chain challenge being faced by Cheplapharm currently?
  • How long do you think it will take for Cheplapharm to resolve these product availability issues?
  • Which of the following Cheplapharm’s recent acquisitions have created issues for the company?
  • How long do you think it will take for Cheplapharm to gain back the market share lost due to its recent issues?
  • What is your general outlook on the future of the company?
  • In your opinion, which aspect of Cheplapharm’s business model is its greatest strength and which one is its greatest weakness, if any?
  • How do you expect the size of the German pharmaceutical industry to change in the next 1 year?

Access

This survey is available to subscribers of the Healthcare (HC) sector (Limited subscriptions and above). This offer includes the raw data file and a high-level presentation through PowerPoint. Please contact your GLG representative for details on your firm’s access.

DISCLAIMER

Please be advised that GLG Network Surveys operate differently than traditional GLG consultations, surveys, teleconferences, etc. and it is advisable that you consult with your firm’s legal and/or compliance department to review your use of the product and the payment for such work under your current subscription. 

By downloading this document and/or participating in the Network Survey, you understand and agree that the information and material provided by GLG, including survey results and survey proposal information, is provided for your own insight and informational purposes only. You further acknowledge and agree that this is a Network Survey for multiple GLG clients, and the results will be provided to all GLG clients that agree to participate in the Network Survey and GLG clients that agree to purchase the Survey results in the future. All survey results do not constitute investment advice or a recommendation. In using this Survey, you agree to hold Gerson Lehrman Group and the Survey respondents harmless and free of all liability as a result of your use of this Network Survey, other than liability resulting from the gross negligence or wilful misconduct of the protected party. You otherwise agree to be bound by Gerson Lehrman Group’s Usage Policies in your interactions with Gerson Lehrman Group and your receipt of services. These Survey results are for are for client’s own use and client shall not redistribute, disseminate, publish, or display the same, in whole or in part, to any third parties or publicly without the prior written permission of Gerson Lehrman Group, except explicitly set forth in your agreement with GLG. This survey will be double-blinded to both client and respondent. GLG reserves the right to restrict the number of clients that can pre-commit access. These Network Surveys are priced outside of standard GLG subscriptions but at a substantially reduced price to commissioning a fully proprietary GLG Network Survey. Upon finding these terms acceptable, please send an affirmative confirmation via email, which GLG will file in its records. Once confirmed, please note that the Client’s agreement to purchase the Network Survey is a legally binding and irrevocable commitment. If the survey is not included within your subscription, GLG will invoice Client for the fees due for the Network Survey. Please note that some respondents may not be Network Members, and the Terms and Conditions of Network Membership would not apply to such respondents and detailed records for them will not be available aside from the information that GLG capture in the Network Survey.